[Arterial hypertension and diabetes]

Area of Science:

• Endocrinology and Metabolism
• Cardiovascular Medicine
• Nephrology

Context:

• Metabolic syndrome, including insulin resistance, hyperinsulinemia, and lipoprotein abnormalities, frequently coexists with hypertension.
• These metabolic derangements can be identified early in life and have a heritable component.
• Insulin resistance may play a primary role in the development of hypertension and associated metabolic issues.

Purpose:

• To explore the intricate relationship between hypertension, insulin resistance, and diabetes.
• To highlight the compounded risks of diabetic heart disease and nephropathy in hypertensive individuals.
• To discuss potential therapeutic strategies, such as angiotensin-converting-enzyme inhibitors, for mitigating complications.

Summary:

• Hypertension exacerbates diabetic cardiomyopathy, leading to more severe coronary artery disease and structural/functional heart abnormalities.
• In non-insulin-dependent diabetes, hypertension significantly elevates the risk of nephropathy, with microalbuminuria being a key mortality predictor.
• Angiotensin-converting-enzyme inhibitors show promise in delaying nephropathy progression in hypertensive, diabetic patients.

Impact:

• Understanding these links is vital for developing targeted interventions to prevent severe complications in patients with coexisting hypertension and diabetes.
• Further clinical trials are necessary to optimize treatment strategies for reducing cardiovascular disease endpoints in this high-risk population.
• This research underscores the importance of managing metabolic factors in hypertensive patients to prevent long-term organ damage.